KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Operating Leases (2019 - 2025)

TherapeuticsMD (TXMD) has disclosed Operating Leases for 7 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 6.34% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Sep 2025, down 6.34%, and an annual FY2024 reading of $5.5 million, down 30.77% over the prior year.
  • Operating Leases was $5.4 million for Q3 2025 at TherapeuticsMD, down from $5.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.5 million in Q1 2021 and bottomed at $5.4 million in Q3 2025.
  • Average Operating Leases over 5 years is $7.1 million, with a median of $7.5 million recorded in 2022.
  • The sharpest move saw Operating Leases increased 8.63% in 2023, then crashed 30.77% in 2024.
  • Year by year, Operating Leases stood at $8.1 million in 2021, then fell by 8.61% to $7.4 million in 2022, then rose by 8.63% to $8.0 million in 2023, then plummeted by 30.77% to $5.5 million in 2024, then fell by 2.36% to $5.4 million in 2025.
  • Business Quant data shows Operating Leases for TXMD at $5.4 million in Q3 2025, $5.7 million in Q2 2025, and $6.0 million in Q1 2025.